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Abstract
Background: In this study we examined the role of Siglec-F, a receptor highly expressed on eosinophils, in
contributing to mucus expression, airway remodeling, and Siglec-F ligand expression utilizing Siglec-F deficient
mice exposed to chronic allergen challenge.
Methods: Wild type (WT) and Siglec-F deficient mice were sensitized and challenged chronically with OVA for one
month. Levels of airway inflammation (eosinophils), Siglec-F ligand expresion and remodeling (mucus, fibrosis,
smooth muscle thickness, extracellular matrix protein deposition) were assessed in lung sections by image analysis
and immunohistology. Airway hyperreactivity to methacholine was assessed in intubated and ventilated mice.
Results: Siglec-F deficient mice challenged with OVA for one month had significantly increased numbers of BAL
and peribronchial eosinophils compared to WT mice which was associated with a significant increase in mucus
expression as assessed by the number of periodic acid Schiff positive airway epithelial cells. In addition, OVA
challenged Siglec-F deficient mice had significantly increased levels of peribronchial fibrosis (total lung collagen,
area of peribronchial trichrome staining), as well as increased numbers of peribronchial TGF-b1+ cells, and
increased levels of expression of the extracellular matrix protein fibronectin compared to OVA challenged WT mice.
Lung sections immunostained with a Siglec-Fc to detect Siglec-F ligand expression demonstrated higher levels of
expression of the Siglec-F ligand in the peribronchial region in OVA challenged Siglec-F deficient mice compared
to WT mice. WT and Siglec-F deficient mice challenged intranasally with IL-4 or IL-13 had significantly increased
levels of airway epithelial Siglec-F ligand expression, whereas this was not observed in WT or Siglec-F deficient
mice challenged with TNF-a. There was a significant increase in the thickness of the peribronchial smooth muscle
layer in OVA challenged Siglec-F deficient mice, but this was not associated with significant increased airway
hyperreactivity compared to WT mice.
Conclusions: Overall, this study demonstrates an important role for Siglec-F in modulating levels of chronic
eosinophilic airway inflammation, peribronchial fibrosis, thickness of the smooth muscle layer, mucus expression,
fibronectin, and levels of peribronchial Siglec-F ligands suggesting that Siglec-F may normally function to limit
levels of chronic eosinophilic inflammation and remodeling. In addition, IL-4 and IL-13 are important regulators of
Siglec-F ligand expression by airway epithelium.
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Background
Siglec-F (Sialic acid-binding Ig-superfamily lectin-F)
belongs to the CD33-related Siglec (CD33rSiglec)
family which are a subclass of Siglecs defined by their
mutual sequence similarity and clustered gene localiza-
tion (chromosome 7 in mouse; chromosome 19q in
humans) [1]. Eosinophils express a restricted profile of
Siglecs [2-5]. Of the eight mouse Siglecs and fourteen
human Siglecs that have been identified, eosinophils
are reported to highly express significant levels of
Siglec-F in mice [2-5] and its functionally convergent
ortholog Siglec-8 in human eosinophils [6-8]. Most of
the CD33rSiglecs are expressed on cells involved in
innate immunity, such as monocytes, granulocytes,
macrophages and natural killer cells [1]. Siglec-F is a
transmembrane receptor comprising a ligand binding
V-set domain, three C-2 domains, a transmembrane
domain, and a cytoplasmic ITIM motif (immunorecep-
tor tyrosine-based inhibitory motif), which is known to
be involved in inhibitory signaling pathways in the
immune system [9,10]. Support for inhibitory signaling
by the cytoplasmic domain of CD33rSiglecs have come
from studies which have demonstrated that antibody
cross-linking of several CD33rSiglecs results in inhibi-
tion of cellular-activation signals, arrest of prolifera-
tion, or induction of apoptosis [11-13].
Siglec-F is highly expressed on mouse eosinophils [5]
and levels of Siglec-F are up-regulated on peripheral
blood eosinophils following acute OVA challenge in
wild type (WT) mice [5]. We have generated Siglec-F
deficient mice and demonstrated that these mice have
similar baseline levels of peripheral blood eosinophils as
do WT mice [5]. However, following acute OVA chal-
lenge Siglec-F deficient mice have significantly increased
numbers of eosinophils in the bone marrow, blood, and
lung compared to WT mice [5]. These studies in Siglec-
F deficient mice suggest that Siglec-F plays an inhibitory
role in acute eosinophilic inflammation. Studies with an
anti-Siglec-F Ab have demonstrated that it reduces
levels of eosinophilic inflammation and induces eosino-
phil apoptosis when administered in mouse models of
gastro-intestinal eosinophilic inflammation [14], lung
eosinophilic inflammation [15], or a mouse model of the
hypereosinophilic syndrome [16]. Although studies have
examined the role of Siglec-F utilizing Siglec-F deficient
mice in acute antigen challenge models of asthma [5],
studies have not utilized Siglec-F deficient mice to
examine whether Siglec-F plays a role in chronic antigen
induced airway remodeling which is the focus of this
study. As eosinophils may contribute to airway remodel-
ing [7,17], we examined whether Siglec-F deficient mice
would have increased levels of airway remodeling, and
deposition of extracellular matrix proteins in the airway
in vivo. In addition, as in previous studies we have
demonstrated that WT mice challenged with allergen
have increased levels of expression of Siglec-F ligands in
the airway epithelium and peribronchial cells [3,5], we
examined whether the absence of Siglec-F receptors in
Siglec-F deficient mice would modulate levels of Siglec-
F ligands expressed in the airway of Siglec-F deficient
compared to WT mice.
Methods
Mouse Model of Chronic OVA-induced Eosinophilic
Inflammation and Airway Remodeling
The mouse model of OVA induced airway remodeling
has previously been described [7,18]. In brief, eight-to
ten-wk-old Siglec-F deficient mice (n = 16/group) [5]
and WT mice (n = 16/group) on a background of C57/
Black were immunized sc on days 0, 7, 14, and 21 with
25 µg of OVA (grade V, Sigma) adsorbed to 1 mg of
alum (Aldrich) in 200 µl of normal saline. Intranasal
OVA challenges (20 µg/50 µl in PBS) were administered
on days 27, 29, and 31 under isoflurane (Vedco, St.
Joseph, MO) anesthesia. Intranasal OVA challenges
were then repeated twice a week for 4 weeks. Age-and
sex-matched control mice were sensitized but not chal-
lenged with OVA during the study. Mice were sacrificed
24 h after the final OVA challenge and bronchoalveolar
lavage (BAL) fluid was collected by lavaging the lung
with 1 mL PBS via a tracheal catheter [5]. Lungs from
the different experimental groups were processed as a
batch for either histological staining or immunostaining
under identical conditions. Stained and immunostained
slides were all quantified under identical light micro-
scope conditions, including magnification (x20), gain,
camera position, and background illumination. All
animal experimental protocols were approved by the
University of California, San Diego Animal Subjects
Committee.
Blood, Bone marrow, BAL, and peribronchial eosinophils
Peripheral blood was collected from mice by cardiac punc-
ture into EDTA-containing tubes as previously described
[5]. Erythrocytes were lysed using a 1:10 solution of 100
mM potassium carbonate-1.5 M ammonium chloride [5].
The remaining cells were re-suspended in 1 mL PBS.
Bone marrow cells were flushed from femurs with 1 mL
PBS, centrifuged, and re-suspended in 1 mL PBS as pre-
viously described [5]. BAL was collected by lavaging the
lung with 1 mL PBS via a tracheal catheter as previously
described [5]. BAL was centrifuged, the supernatant was
collected and frozen at -80°C, and cells were re-suspended
in 1 mL PBS. Total leukocytes were counted using a
hemocytometer. To perform differential cell counts,
200 µL re-suspended BAL cells, peripheral-blood
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leukocytes, or 20 µL bone marrow cell suspensions was
cytospun onto microscope slides and air-dried. Slides were
stained with Wright-Giemsa and differential cell counts
were performed under a light microscope [5].
Lung sections were processed for major basic protein
(MBP) immunohistochemistry as previously described
[5], using an anti-mouse MBP Ab (kindly provided by
James Lee PhD, Mayo Clinic, Scottsdale, Arizona). The
number of individual cells staining positive for MBP in
the peribronchial space were counted using a light
microscope. Results are expressed as the number of
peribronchial cells staining positive for MBP per
bronchiole with 150-200 µm of internal diameter. At
least ten bronchioles were counted in each slide.
Airway mucus expression
To quantitate the level of mucus expression in the
airway, the number of periodic acid Schiff (PAS)-positive
and PAS-negative epithelial cells in individual bronch-
ioles were counted as previously described in this
laboratory [7]. At least ten bronchioles were counted in
each slide. Results are expressed as the percentage of
PAS-positive cells per bronchiole, which is calculated
from the number of PAS-positive epithelial cells per
bronchus divided by the total number of epithelial cells
of each bronchiole.
Peribronchial trichrome staining
Lungs in the different groups of mice were equivalently
inflated with an intratracheal injection of the same
volume of 4% paraformaldehyde solution (Sigma Chemi-
cals, St. Louis, MO) to preserve the pulmonary architec-
ture. The area of peribronchial trichrome staining in
paraffin-embedded lungs was outlined and quantified
under a light microscope (Leica DMLS, Leica Microsys-
tems) attached to an image analysis system (Image-Pro
plus, Media Cybernetics) as previously described [7].
Results are expressed as the area of trichrome staining
per µm length of basement membrane of bronchioles
150-200 µm of internal diameter.
Lung collagen assay
The amount of lung collagen was measured as pre-
viously described in this laboratory (8) with a collagen
assay kit that uses a dye reagent that selectively binds to
the [Gly-X-Y]n tripeptide sequence of mammalian col-
lagens (Biocolor, Newtonabbey, UK). In all experiments,
a collagen standard was used to calibrate the assay.
Peribronchial TGF-b1 + cells
The number of peribronchial TGFb-1+ cells were quan-
titated by immunohistochemistry using an anti-TGF-b1
Ab as previously described in this laboratory [7].
Lung cytokines and chemokines
Levels of lung cytokines (IL-5, IL-13) and lung chemo-
kines (eotaxin-1, RANTES) were quantitated by ELISA
(R&D Systems, Minneapolis, MN) in lung tissue as pre-
viously described [18]. In brief, lung tissue was homoge-
nized in lysis buffer, and lung supernatants (obtained by
centrifugation 10,000 g for 20 min) were passaged
through an 0.8-µm pore size filter and frozen at-80°C in
polypropylene tubes until used in assays [18]. The IL-5,
IL-13, and RANTES ELISA assays each had a sensitivity
of 31 pg/ml, and the eotaxin-1 assay a sensitivity of
16 pg/ml.
Lung LTC4 levels
As leukotriene C4 (LTC4) is a product of eosinophils [19],
and LTC4 is associated with airway remodeling [20], we
determined levels of LTC4 in lung tissue using a using a
LTC4 ELISA (Neogen, Lexington, KY). The sensitivity of
the LTC4 assay was 0.04 ng/ml.
Detection of extracellular matrix protein fibronectin
Lung sections were processed for fibronectin immuno-
histochemistry using a rabbit anti-mouse fibronectin Ab
(Abcam, Cambridge, MA). The area of peribronchial
fibronectin staining was outlined and quantified under a
light microscope (Leica DMLS) attached to an image
analysis system (Image-Pro plus) as described for tri-
chrome staining. Results are expressed as the area of
fibronectin staining per µm length of basement mem-
brane of bronchioles 150-200 µm of internal diameter.
Siglec-F ligand expression
Cryostat sections of lung tissues were incubated with a
recombinant Siglec-F-Fc (or as a negative control
R114A Siglec-F-Fc) and detected using the immunoper-
oxidase method as previously described [5]. R114A
Siglec-F-Fc is a specific negative control comprising the
same Siglec-F-Fc with a single amino acid mutation (i.e.
an Arg-Ala mutation that eliminates sialic acid recogni-
tion)[5]. The Siglec-F-Fc comprises the extracellular
domains of Siglec-F involved in sialic acid recognition
fused with the Fc portion of human IgG. This probe can
be used to detect specific ligands on cells and in tissue
sections [5]. In previous studies in WT mice we have
demonstrated that following OVA challenge Siglec-F
ligands are expressed in airway epithelium and peribron-
chial cells (eosinophils, macrophages)[5]. Following lung
immunostaining, the area of epithelial Siglec-F-Fc
immunostaining was outlined and quantified using a
light microscope (Leica DMLS) attached to an image-
analysis system (Image-Pro Plus). Results are expressed
as the area of epithelial immunostaining per µm length
of epithelial basement membrane of bronchioles with
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150-250 µm internal diameter. At least ten bronchioles
were counted in each slide. In addition to quantitating
the levels of Siglec-F ligand expression by airway epithe-
lial cells, we also quantitated the number of peribron-
chial cells expressing Siglec-F ligands. Results are
expressed as the number of peribronchial cells staining
positive for Siglec-F-Fc per bronchiole with 150-200 µm
of internal diameter.
Effect of cytokines on Siglec-F Ligand expression in WT
mice
Eight week old WT C57BL/6 mice or Siglec-F deficient
mice (n = 3/group) were challenged intranasally with 0.6
µg of each individual cytokine (IL-4, IL-13, TNF-a, or
PBS diluent control) (R&D Systems, Minneapolis, MN)
under isofluorane anesthesia using a modification of a
previously published protocol [21]. The dose of cytokine
administered intranasally was chosen based on dosages
used in studies in a previously published protocol [21].
Twenty four hours after each individual cytokine or
diluent challenge, the mice were sacrificed. BAL was
obtained for determination of eosinophil and neutrophil
cell counts, and the lungs were processed for immuno-
histology to detect Siglec-F ligand expression in airway
epithelium and peribronchial MBP+ eosinophils as
described above.
Peribronchial Smooth Muscle Layer Thickness
Lung sections were also immunostained with an anti-a-
smooth muscle actin primary antibody (Sigma-Aldrich)
to detect peribronchial smooth muscle cells as pre-
viously described in this laboratory [22]. Species-and
isotype-matched Abs were used as controls in place of
the primary Ab. The area of peribronchial a-smooth
muscle actin staining in paraffin-embedded lungs was
outlined and quantified under a light microscope (Leica
DMLS) attached to an image analysis system (Image-Pro
plus) as previously described [7]. Results are expressed
as the area of peribronchial a-smooth muscle actin
staining per µm length of basement membrane of
bronchioles 150-200 µm of internal diameter.
Airway hyperreactivity to Mch
Airway responsiveness to methacholine (MCh) was
assessed 24 h after the final OVA challenge in intubated
and ventilated mice (flexiVent ventilator; Scireq, Mon-
treal, PQ, Canada) anesthetized with ketamine (100 mg/
kg) and xylazine (10 mg/kg) intraperitoneally as pre-
viously described [23]. The dynamic airway resistance
(Raw) was determined using Scireq software in mice
exposed to nebulized PBS and MCh (3, 24, 48 mg/ml).
The following ventilator settings were used: tidal volume
(10 ml/kg), frequency (150/min), positive end-expiratory
pressure (3 cmH2O).
Statistical Analysis
Results in the different groups of mice were compared
by ANOVA using the non-parametric Kruskal-Wallis
test followed by post-testing using Dunn’s multiple com-
parison of means. All results are presented as mean ±
SEM. A statistical software package (Graph Pad Prism,
San Diego, CA) was used for the analysis. P values of <
0.05 were considered statistically significant.
Results
Chronic OVA challenged Siglec-F deficient mice have
increased levels of BAL eosinophils and peribronchial
eosinophils
Chronic OVA challenge in WT mice induced a signifi-
cant increase in the number of BAL eosinophils (p <
0.0001)(WT OVA vs WT no OVA)(Figure 1A), as well
as a significant increase in the number of peribronchial
eosinophils (p < 0.0001)(WT OVA vs WT no OVA)(Fig-
ure 1B) compared to non-OVA challenged mice. The
number of BAL eosinophils in chronic OVA challenged
Siglec-F deficient mice were significantly higher than
that in chronic OVA challenged WT mice (18.0 ± 3.9 vs
3.4 ± 1.0 BAL eosinophils × 104)(Siglec-F deficient OVA
vs WT OVA)(p < 0.001)(Figure 1A). Similarly, the num-
ber of peribronchial eosinophils in chronic OVA chal-
lenged Siglec-F deficient mice were significantly higher
than that in chronic OVA challenged WT mice (34.0 ±
3.1 vs 24.8 ± 2.7 MBP+ eosinophils/bronchus)(Siglec-F
deficient OVA vs WT OVA)(p < 0.04)(Figure 1B). The
magnitude of the increase in BAL eosinophils in Siglec-
F deficient compared to WT mice (5.3 fold increase),
was greater than the magnitude of the increase in peri-
bronchial eosinophils in Siglec-F deficient compared to
WT mice (1.4 fold increase).
Chronic OVA challenged Siglec-F deficient mice have
increased levels of bone marrow eosinophils and
peripheral blood eosinophils
Chronic OVA challenge in WT mice induced a signifi-
cant increase in the number of peripheral blood eosino-
phils (p < 0.003)(WT OVA vs WT no OVA)(Figure 1C),
as well as a slight but statistically insignificant increase
in the number of bone marrow eosinophils (p = ns)(WT
OVA vs WT no OVA)(Figure 1D). The number of bone
marrow eosinophils in chronic OVA challenged Siglec-F
deficient mice was significantly increased compared to
that of chronic OVA challenged WT mice (10.1 ± 0.5 vs
3.4 ± 0.8% eosinophils)(Siglec-F deficient OVA vs WT
OVA)(p < 0.001)(Figure 1D). Similarly, the percentage
of peripheral blood eosinophils in chronic OVA chal-
lenged Siglec-F deficient mice was significantly increased
compared to that of chronic OVA challenged WT mice
(4.1 ± 0.7 vs 1.7 ± 0.3% eosinophils)(Siglec-F deficient
OVA vs WT OVA)(p < 0.003)(Figure 1C).
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Chronic OVA challenged Siglec-F deficient mice have
increased levels of airway mucus
Chronic OVA challenge in WT mice induced a signifi-
cant increase in the number of PAS+ mucus cells (p <
0.0001)(WT OVA vs WT no OVA)(Figure 2A) com-
pared to non-OVA challenged mice. Siglec-F deficient
mice challenged with OVA had a significant increase in
the percentage of PAS+ mucus cells compared to OVA
challenged WT mice (42.7 ± 3.5 vs 21.8 ± 3.0% PAS+
cells/bronchus)(Siglec-F deficient OVA vs WT OVA)(p
< 0.0001)(Figure 2A-2E).
Chronic OVA challenged Siglec-F deficient mice have
increased levels of peribronchial fibrosis
Chronic OVA challenge in WT mice induced a signifi-
cant increase in levels of peribronchial fibrosis as
assessed by either increases in lung collagen (p <
0.0001)(WT OVA vs WT no OVA)(Figure 3A), or the
area of peribronchial trichrome staining (p < 0.0001)
(WT OVA vs WT no OVA)(Figure 3B) compared to
non-OVA challenged mice. The amount of lung col-
lagen in chronic OVA challenged Siglec-F deficient mice
was significantly higher than that in chronic OVA chal-
lenged WT mice (1,382 ± 77 vs 1,005 ± 38 µg collagen/
lung)(Siglec-F deficient OVA vs WT OVA)(p < 0.002)
(Figure 3A).The area of peribronchial trichrome staining
was also significantly higher in chronic OVA challenged
Siglec-F deficient mice compared to chronic OVA chal-
lenged WT mice (p < 0.01)(Figure 3B).
Chronic OVA challenged Siglec-F deficient mice have
increased numbers of peribronchial TGF-b1+ cells but no
increase in LTC4
Chronic OVA challenge in WT mice induced a signifi-
cant increase in the number of peribronchial cells
immunostaining positive for TGF-b1 compared to non-
OVA challenged WT mice (2.2 ± 0.7 vs 65.8 ± 3.4)(WT
no OVA vs WT OVA)((p < 0.0001)(Figure 3C). The
number of peribronchial cells immunostaining positive
for TGF-b1 in chronic OVA challenged Siglec-F defi-
cient mice was significantly higher than that in chronic
OVA challenged WT mice (p < 0.001)(Figure 3C).
Chronic OVA challenge in WT mice induced a sig-
nificant increase in levels of lung LTC4 compared to
non-OVA challenged mice (3.8 ± 0.4 vs 6.6 ± 0.9 ng/
ml LTC4)(WT no OVA vs WT OVA)((p < 0.02)(Figure
3D). Levels of lung LTC4 in chronic OVA challenged
Siglec-F deficient mice were significantly higher than
in non-OVA challenged Siglec-F deficient mice (p <
0.02), but these levels were not significantly different
Figure 1 Levels of BAL, lung, blood, and bone marrow eosinophils in Siglec-F deficient vs WT mice. Different groups of Siglec-F deficient
or WT mice were subjected to chronic OVA challenge. Non-OVA challenged mice served as a control. Eosinophils in bronchoalveolar lavage
(BAL), blood, and bone marrow were quantitated in cytospin slides stained with Wright-Giemsa, whereas eosinophils in lung sections were
quantitated by immunostaining with an anti-MBP Ab. Chronic OVA challenge in WT mice induced a significant increase in BAL eosinophils (p <
0.0001*)(Fig 1A), peribronchial eosinophils (p < 0.0001*)(Fig 1B), and blood eosinophils (p < 0.003*)(Fig 1C)(WT no OVA vs WT OVA). Levels of
eosinophils in OVA challenged Siglec-F deficient mice were significantly increased compared to WT mice challenged with OVA in the BAL (p <
0.001#)(Fig 1A), lung (p < 0.04#)(Fig 1B), blood (p < 0.003#)(Fig 1C), and bone marrow (p < 0.001#)(Fig 1D)(n = 16 mice/group).
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from that noted in chronic OVA challenged WT mice
(Figure 3D).
Chronic OVA challenged Siglec-F deficient mice express
increased levels of the extracellular matrix protein
fibronectin
Chronic OVA challenge in WT mice induced a signifi-
cant increase in the area of peribronchial immunostain-
ing of the extracellular matrix protein fibronectin
compared to non-OVA challenged mice (p < 0.0001)
(Figure 4A). The area of peribronchial fibronectin
immunostaining in chronic OVA challenged Siglec-F
deficient mice was significantly higher than that in
chronic OVA challenged WT mice (4.6 ± 0.3 vs 3.3 ±
0.3)(Siglec-F deficient OVA vs WT OVA)(p < 0.01)
(Figure 4A-4E.
Levels of lung cytokines and chemokines in chronic OVA
challenged Siglec-F deficient mice
Chronic OVA challenge in WT mice induced a signifi-
cant increase in lung levels of IL-5 (p < 0.03)(Figure
5A), IL-13 (p < 0.04)(Figure 5B), and eotaxin-1 (p <
0.01)(Figure 5C) compared to WT mice not challenged
with OVA. The increase in levels of lung RANTES in
Figure 2 Levels of mucus expression in Siglec-F deficient vs WT mice. Different groups of Siglec-F deficient or WT mice were subjected to
chronic OVA challenge. Non-OVA challenged mice served as a control. The level of mucus expression was quantitated in lung sections by PAS
staining using a light microscope objective at 20× (Fig 2 A-E). Chronic OVA challenge in WT mice induced a significant increase in the number
of PAS+ mucus cells (p = 0.0001*)(WT no OVA vs WT OVA)(Fig 2A; Fig 2B vs Fig 2D). Levels of mucus expression were significantly increased in
OVA challenged Siglec-F deficient mice compared to OVA challenged WT mice (p = 0.0001#)(Fig 2A; Fig 2E vs Fig 2D)(n = 16 mice/group).
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WT mice following OVA challenge was not statistically
significant (899 ± 53 vs 1,132 ± 134)(WT no OVA vs
WT OVA)(p = ns).
Levels of lung IL-5 (Figure 5A) and IL-13 (Figure 5B)
were similar in OVA challenged Siglec-F deficient and
OVA challenged WT mice. Levels of lung eotaxin-1 (p
< 0.04)(Figure 5C), and RANTES (p < 0.02)(Figure 5D)
were increased in Siglec-F deficient compared to WT
mice challenged with OVA.
Chronic OVA challenged Siglec-F deficient mice express
increased levels of peribronchial Siglec-F ligands
Image analysis quantitation demonstrated that there was
a significant increase in the number of peribronchial
cells immunostaining positive with the Siglec-F-Fc in
WT mice exposed to chronic OVA challenge compared
to non-OVA challenged WT mice (p < 0.0001)(Figure
6A). Similarly, the area of airway epithelium immunos-
taining positive with the Siglec-F-Fc demonstrated a sig-
nificant increase in WT mice exposed to chronic OVA
challenge compared to non-OVA challenged WT mice
(p < 0.0001)(Figure 6B). Lung sections immunostained
with the control R114A Siglec-F-Fc did not detect posi-
tive staining of peribronchial cells or airway epithelial
cells.
The number of peribronchial cells immunostaining
positive with the Siglec-F-Fc was significantly higher in
chronic OVA challenged Siglec-F deficient mice com-
pared to chronic OVA challenged WT mice (48.6 ± 4.7
vs 28.5 ± 4.1 peribronchial Siglec-Fc+ cells) (Siglec-F
deficient OVA vs WT OVA)(p < 0.01)(Figure 6A). In
contrast, the area of airway epithelial immunostaining
positive with the Siglec-F-Fc in chronic OVA challenged
Siglec-F deficient mice was similar to that observed in
Figure 3 Levels of peribronchial fibrosis, TGF-b1+ cells, and LTC4 levels in Siglec-F deficient vs WT mice. Different groups of Siglec-F
deficient or WT mice were subjected to chronic OVA challenge. Non-OVA challenged mice served as a control. Levels of peribronchial fibrosis
were quantitated by assaying collagen levels in lungs (Fig 3A), as well as by quantitating the area of peribronchial trichrome staining by image
analysis (Fig 3B). Levels of mediators of lung fibrosis were assessed by quantitating the number of peribronchial cells immunostaining positive
for TGF-b1 (Fig 3C) as well as levels of LTC4 in BAL (Fig 3D) by Elisa. Chronic OVA challenge in WT mice induced a significant increase in lung
collagen (p < 0.0001*)(Fig 3A), and the area of peribronchial trichrome staining (p < 0.0001*)(Fig 3B), the number of peribronchial TGF-b1+ cells
(p < 0.0001*)(Fig 3C), and levels of BAL LTC4 (p < 0.02*)(WT no OVA vs WT OVA). Levels of lung collagen were significantly increased in OVA
challenged Siglec-F deficient mice compared to WT mice challenged with OVA (p < 0.002#)(WT OVA vs Siglec-F OVA)(Fig 3A), as was the area of
peribronchial trichrome staining (p < 0.01#)(Fig 3B), and the number of peribronchial TGF-b1+ cells (p < 0.001)(Fig 3C)(n = 16 mice/group).
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chronic OVA challenged WT mice (Siglec-F deficient
OVA vs WT OVA)(p = ns)(Figure 6B).
IL-4 and IL-13 up-regulate expression of Siglec-F ligands
in WT and Siglec-F deficient mice
In WT mice administration of either IL-4 (p < 0.001) or
IL-13 (p < 0.001) induced significantly increased levels
of Siglec-F ligand expression by peribronchial cells and
airway epithelium compared to control diluent challenge
(Figure 7A-C, 7E-F). In contrast, administration of
TNF-a (p = ns) did not induce significant Siglec-F
ligand expression by airway epithelium (p = ns) but
induced a slight but statistically significant increase in
Siglec-F ligand expressing peribronchial cells (p < 0.01)
(Fig. 7E-F).
In Siglec-F deficient mice, similar results were
observed with both IL-4 and IL-13 inducing increased
Siglec-F ligand expression to a similar degree in both
peribronchial cells (Figure 7E) and airway epithelium
(Figure 7F), while TNFa did not significantly induce
Siglec-F ligand expression in airway epithelium (Figure
7E and 7F). In comparing WT and Siglec-F deficient
mice, responses to these three cytokines were similar in
the number of Siglec-F ligand+ peribronchial cells (Fig-
ure 7E). Although both IL-4 and IL-13 induced strong
upregulation of Siglec-F ligand expression by airway
Figure 4 Levels of peribronchial fibronectin in Siglec-F deficient vs WT mice. Different groups of Siglec-F deficient or WT mice were
subjected to chronic OVA challenge. Non-OVA challenged mice served as a control. Lung sections were immunostained with an anti-fibronectin
Ab and the area of peribronchial fibronectin immunostaining determined by image analysis using a light microscope objective at 20× (Figure 4
A-E). Chronic OVA challenge in WT mice induced a significant increase the area of peribronchial fibronectin immunostaining (p < 0.0001*)(Fig
4A; Fig 4B vs Fig 4D)(WT no OVA vs WT OVA). The area of peribronchial fibronectin immunostaining was also significantly increased in OVA
challenged Siglec-F deficient compared to OVA challenged WT mice (p < 0.01#)(Fig 4A; Fig 4E vs Fig 4D)(n = 16 mice/group).
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epithelium in both WT and Siglec-F deficient mice (Fig-
ure 7F), levels of Siglec-F ligands in airway epithelium
were slightly lower in Siglec-F deficient vs WT mice
induced by IL-13 (p = 0.02) but not IL-4 (p = 0.10) (Fig-
ure 7F). The number of MBP+ peribronchial cells were
higher in Siglec-F deficient mice compared to WT mice
administered IL-4 (p = 0.05) or IL-13 (p = 0.01)(Figure
7H). Administration of TNFa induced a significant BAL
neutrophil response in both WT (p = 0.03)(Figure 7I)
and Siglec-F deficient mice (p = 0.03)(Figure 7I). In con-
trast, IL-4 and IL-13 induced a strong BAL eosinophil
response in both WT and Siglec-F deficient mice (7G).
Figure 5 Levels of lung cytokines and chemokines in Siglec-F deficient vs WT mice. Different groups of Siglec-F deficient or WT mice were
subjected to chronic OVA challenge. Non-OVA challenged mice served as a control. Levels of IL-5 (Fig 5A), IL-13 (Fig 5B), eotaxin-1 (Fig 5C), and
RANTES (Fig 5D) were measured in lung by ELISA. Chronic OVA challenge in WT mice induced a significant increase in IL-5 (p < 0.03*)(Fig 5A),
IL-13 (p < 0.04*)(Fig 5B), and eotaxin-1 (p < 0.01*)(Fig 5C), but not RANTES (p = ns)(Fig 5D). Levels of IL-5 (Fig 5A) and IL-13 (Fig 5B) were no
different in OVA challenged Siglec-F deficient mice compared to WT mice challenged with OVA, while levels of eotaxin-1 (p < 0.04#) (Fig 5C)
and RANTES (p < 0.02#)(Fig 5D) were increased in Siglec-F deficient mice compared to WT mice challenged with OVA (n = 16 mice/group).
Figure 6 Quantitation of Siglec-F ligands in airway epithelial cells and peribronchial inflammatory cells. Lung sections from non-OVA or
chronic OVA challenged WT or Siglec-F deficient mice were immunostained with a Siglec-F-Fc or a control Fc. The number of peribronchial cells
(Fig 6A), as well as the area of airway epithelial cells (Fig 6B) immunostaining positive for Siglec-F-Fc was quantitated by image analysis. OVA
challenged WT mice had significantly increased numbers of peribronchial cells immunostaining positive with the Siglec-F-Fc (p = 0.0001*)(Fig
6A) and significantly increased levels of airway epithelial cell Siglec-F-Fc immunostaining compared to non-OVA challenged WT mice (p =
0.0001*)(Fig 6B). Siglec-F deficient mice challenged with OVA had significantly increased numbers of peribronchial cells immunostaining positive
for Siglec-F-Fc compared to OVA challenged WT mice (p = 0.01#)(Fig 6A), whereas airway epithelial Siglec-F-Fc immunostaining was similar in
OVA challenged Siglec-F deficient and WT mice (Fig 6B)(n = 16 mice/group).
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Chronic OVA challenged Siglec-F deficient mice have
increased smooth muscle thickness
Chronic OVA challenge in WT mice induced a signifi-
cant increase in the thickness of the peribronchial
smooth muscle layer (5.3 ± 0.2 vs 3.1 ± 0.1 µm)(p <
0.0001)(WT OVA vs WT no OVA)(Figure 8A) com-
pared to non-OVA challenged WT mice. Siglec-F defi-
cient mice challenged chronically with OVA had a
modest (approximately 20%), but statistically significant,
increase in the thickness of the peribronchial smooth
muscle layer (6.3 ± 0.2 vs 5.3 ± 0.2 µm)(p < 0.003)
(Siglec-F deficient mice OVA vs WT OVA)(Figure 8A)
compared to OVA challenged WT mice.
Chronic OVA challenged Siglec-F deficient mice and AHR
Chronic OVA challenge in WT mice induced a statisti-
cally significant increase in airway responsiveness to
Mch (WT OVA vs WT no OVA, Mch 48 mg/ml)(p <
0.002)(Figure 8B). Siglec-F deficient mice challenged
with OVA had a small but statistically insignificant
Figure 7 Quantitation of Siglec-F ligands in airway epithelial cells and peribronchial inflammatory cells in WT and Siglec-F deficient
mice challenged with IL-4, IL-13 or TNF-a. WT or Siglec-F deficient mice were administered either IL-4, IL-13, TNF-a, or PBS diluent control.
Twenty four hours after each individual cytokine or diluent challenge, the mice were sacrificed. BAL was obtained for determination of
eosinophil and neutrophil cell counts, and the lungs were processed for immunohistology to detect Siglec-F ligand expression and MBP+
peribronchial eosinophils using a light microscope objective at 20×. Administration of either IL-4 (p < 0.001, WT; p < 0.001, Siglec-F deficient) or
IL-13 (p < 0.001, WT; p < 0.001, Siglec-F deficient) induced a similar significant increase in levels of Siglec-F ligand expression by peribronchial
cells (Fig 7A-C, 7E). In contrast, administration of TNF-a induced a small increase in peribronchial Siglec-F ligands (p < 0.01)(Fig 7E), but did not
significantly increase Siglec-F ligand expression by airway epithelium in either WT or Siglec-F deficient mice (p = ns) (Fig 7 D, 7F). Administration
of either IL-4 (p < 0.001 WT; p < 0.001 Siglec-F deficient) or IL-13 (p < 0.001 WT; p < 0.001 Siglec-F deficient) induced significantly increased
levels of Siglec-F ligand expression by airway epithelium (Fig 7A-C, 7F). Although both IL-4 and IL-13 induced strong upregulation of Siglec-F
ligand expression by airway epithelium (Fig 7F), levels of Siglec-F ligands in airway epithelium were slightly lower in Siglec-F deficient vs WT
mice induced by IL-13 (p = 0.02) but not IL-4 (p = 0.10) (Fig 7F). IL-4 induced the strongest eosinophil response in BAL (WT p < 0.03; Siglec-F
deficient p = 0.02)(Fig 7G) and lung (WT p < 0.001; Siglec-F deficient p < 0.001)(Fig 7H), while IL-13 and TNF-a induced a weaker eosinophil
response in BAL (Fig 7G) and lung (Fig 7H). TNF-a, but not IL-4 or IL-13, induced a strong neutrophil response in BAL in both WT (p = 0.03) and
Siglec-F deficient mice (p = 0.03) (Fig 7I)(n = 3 mice/group).
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increase in airway responsiveness compared to WT mice
challenged with OVA (Siglec-F deficient mice OVA vs
WT mice OVA; Mch 48 mg/ml)(p = 0.15)(Figure 8B).
Discussion
In this study we have utilized Siglec-F deficient mice to
demonstrate an important role for Siglec-F in modulat-
ing levels of airway remodeling (peribronchial fibrosis,
thickness of the smooth muscle layer), mucus expres-
sion, deposition of extracellular matrix proteins such as
fibronectin, as well as an important role for Siglec-F in
regulating levels of chronic allergen induced peribron-
chial Siglec-F ligands. This study confirms the impor-
tance of Siglec-F in airway remodeling and extends
results obtained using an anti-Siglec-F Ab in WT mice
[15], to demonstrate an important role for Siglec-F in
mucus expression, deposition of extracellular matrix
proteins such as fibronectin, and regulating levels of
chronic allergen induced peribronchial Siglec-F ligands
which were not demonstrated in previous studies using
an anti-Siglec-F Ab in WT mice [15]. In addition, we
demonstrated that Th2 cytokines such as IL-4 or IL-13
induce equivalent upregulation of Siglec-F ligand expres-
sion by airway epithelium in vivo. In contrast, TNF-a
another cytokine expressed in the remodeled airway
does not significantly regulate airway epithelial Siglec-F
ligand expression, even though it induced a significant
BAL neutrophil response. In addition to airway epithe-
lium we have previously demonstrated that eosinophils
also express Siglec-F ligands [5]. All three cytokines (IL-
4, IL-13, and TNF-a) increased the number of peribron-
chial cells expressing Siglec-F ligands and this was
proportional to the induced lung eosinophil response
which was strongest with IL-4 and IL-13 and signifi-
cantly weaker with TNF-a. As activating Siglec-F recep-
tors with anti-Siglec-F antibodies in vitro induces
apoptosis [5,14-16], the up-regulated expression of
Siglec-F ligands by airway epithelium in response to
Th2 cytokines may be a mechanism by which airway
epithelium downregulates eosinophilic inflammation
when eosinophils come in contact with the airway
epithelium. In vitro studies have demonstrated that a
synthetic Siglec-8 ligand induces human eosinophil
apoptosis [24] underscoring the potential therapeutic
utility of using Siglec ligands to limit eosinophilic
inflammation. Chronic OVA challenge induced a similar
significant increase in levels of lung IL-5 and IL-13 in
Siglec-F deficient and WT mice. However there was a
slight but statistically significant increase in levels of
lung eotaxin-1 and RANTES in chronic OVA challenged
Siglec-F deficient compared to WT mice which may
reflect the increased numbers of peribronchial inflam-
matory cells in chronic OVA challenged Siglec-F defi-
cient capable of expressing these chemokines. This
study also demonstrated that the important eosinophil
product LTC4, a mediator not investigated in previous
studies using an anti-Siglec-F Ab in WT mice [15], was
unlikely to be contributing to enhanced remodeling in
Siglec-F deficient mice. Siglec-F deficient mice chal-
lenged with chronic allergen had significantly enhanced
peribronchial fibrosis, as well as increased mucus
expression, and an increase in the thickness of the
smooth muscle layer. Although Siglec-F deficient mice
had increased thickness of the smooth muscle layer, the
Figure 8 Thickness of the peribronchial smooth muscle layer and airway responsiveness in Siglec-F deficient vs WT mice. Different
groups of Siglec-F deficient or WT mice were subjected to chronic OVA challenge. Non-OVA challenged mice served as a control. The thickness
of the peribronchial smooth muscle layer was quantitated in lung sections (Fig 8A). Chronic OVA challenge in WT mice induced a significant
increase in the thickness of the peribronchial smooth muscle layer (p = 0.0001*)(Fig 8A)(WT no OVA vs WT OVA). The thickness of the
peribronchial smooth muscle layer in OVA challenged Siglec-F deficient mice was significantly increased compared to WT mice challenged with
OVA (p = 0.003#)(Fig 6A). Airway resistance (Raw) was measured (cm H2O.s/ml) in different groups of intubated and ventilated Siglec-F deficient
deficient or WT mice following nebulization of either PBS diluent or MCh (3, 24, 48 mg/ml)(Fig 8B). Chronic OVA challenge in WT mice induced
a significant increase in airway resistance (WT no OVA vs WT OVA; p < 0.002, 48 mg/ml MCh)(Fig 6B). Siglec-F deficient mice challenged with
OVA had a statistically insignificant trend for increased airway responsiveness compared to WT mice (Siglec-F deficient OVA vs WT OVA; p = 0.15,
48 mg/ml MCh)(n = 16 mice/group).
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trend for increased airway responsiveness was not statis-
tically significant.
The mechanism by which Siglec-F deficient mice have
enhanced airway remodeling is not due to a direct effect
of Siglec-F on fibroblasts, epithelial cells, or smooth
muscle as these cells do not express Siglec-F. In the
absence of an allergen stimulus to induce airway inflam-
mation, non-OVA challenged Siglec-F deficient mice do
not have evidence of airway remodeling, again support-
ing the concept that it is the exaggerated inflammatory
response in Siglec-F deficient mice, rather than struc-
tural cells in the airway, that are the primary initiator of
enhanced airway remodeling in Siglec-F deficient mice.
Siglec-F is most highly expressed on eosinophils [5], but
can also be detected on macrophages and activated CD4
+ T cells as previously demonstrated [5]. As Siglec-F
deficiency results in increased numbers of eosinophils in
the allergen challenged lung, one potential explanation
for the enhanced airway remodeling in Siglec-F deficient
mice is the increased numbers of eosinophils in the lung
expressing pro-fibrotic growth factors that may contri-
bute to remodeling including TGF-b1 [7,22]. In support
of this hypothesis are the increased numbers of TGF-b1
+ cells we have identified in Siglec-F deficient mice. The
importance of eosinophils and TGF-b1 to airway remo-
deling is suggested from murine studies in which airway
remodeling is significantly reduced in mice treated with
an anti-TGF-b1 Ab [25], as well as in Smad 3 deficient
mice [22] which have impaired TGF-b signaling. In
addition studies in IL-5 deficient mice [7] as well as in
human subjects with asthma treated with anti-IL-5 [17]
demonstrate reduced numbers of eosinophils, reduced
TGF-b1+ eosinophils, and reduced airway remodeling.
Although several studies show an important role for
eosinophils, TGF-b1, and Smad signaling in airway
remodeling [22,25], there are studies which have
demonstrated that an anti-TGF-b1 Ab does not reduce
remodeling in mice [26], and that an anti-TGF-b1 Ab
increase airway hyperreactivity in mice [27]. Increased
numbers of peribronchial cells expressing TGF-b1 in
chronic OVA challenged Siglec-F decient mice may also
contribute to increased smooth muscle thickness as
TGF-b1 induces airway smooth muscle hypertrophy
[28]. As LTC4 is expressed by eosinophils [19] and has
pro-remodeling potential in asthma [20], we examined
whether Siglec-F deficient mice had increased levels of
lung LTC4 in their remodeled airways. As there was no
significant difference in levels of LTC4 in the remodeled
airways of WT and Siglec-F deficient mice, LTC4 is
unlikely to explain the differences in levels of airway
remodeling in WT and Siglec-F deficient mice. The
mechanism of increased mucus expression in chronic
OVA challenged Siglec-F decient mice at present
unknown. One possible explanation is that the increased
numbers of eosinophils in the airway in Siglec-F defi-
cient mice express increased levels of mediators that can
influence mucus secretion including granule mediators
(ECP, MBP)[29,30], lipid mediators (LTC4)[31], cyto-
kines (IL-13)[31], or other at present unknown media-
tors. Alternatively eosinophils may release a mediator
that influences a second cell type to subsequently influ-
ence mucus expression. Our initial experiments to
address this question demonstrate no differences in
levels of IL-13 or LTC4 between Siglec-F deficient and
WT mice.
In this study we also made the novel observation that
Siglec-F deficient mice had increased levels of peribron-
chial extracellular matrix remodeling as indicated by
increased fibronectin deposition. Fibronectin is a large
extracellular matrix glycoprotein molecule consisting of
two similar subunits of 220-250 kDa [32] that has been
detected in increased amounts in the remodeled airway
in human asthma [33], as well as in fatal asthma [34].
There are two forms of fibronectin, plasma fibronectin
(dimeric and soluble) and cellular or extracellular matrix
fibronectin (multimeric and insoluble)[32]. Extracellular
matrix deposition of fibronectin may enhance airway
remodeling in asthma by contributing to the formation
of collagen fibrils [35], mediate the migration of fibro-
blasts [36], and increase the proliferation of smooth
muscle cells [37]. In addition, fibronectin may enhance
eosinophilc inflammation in the airway through its abil-
ity to increase CC chemokine expression by airway
smooth muscle cells [38].
In this study we demonstrated that Siglec-F plays an
important role in mediating several key features of air-
way remodeling but did not a play a significant role in
mediating AHR. Although mathematical models of
asthma predict that the increased airway wall thickening
in remodeled airways would result in disproportionately
severe airway narrowing and responsiveness [39], studies
in human asthmatics have demonstrated that airway
wall remodeling and thickening in asthma is associated
with reduced rather than increased airway reactivity to
MCh [40]. One potential explanation suggested [41] for
the discrepancy in results between the mathematical
modeling studies and the computerized tomography
scan studies in asthma is that the mathematical model-
ing studies did not fully take into account the potential
effect of airway wall thickening on the mechanical prop-
erties of the airway, e.g., stiffness of the airway [41]. Our
studies with Siglec-F-deficient mice underscore the fact
that a gene such as Siglec-F, which plays a significant
role in mediating several important aspects of airway
remodeling, may not play an essential role in mediating
AHR. Our studies using an anti-Siglec-F Ab in a model
of chronic OVA allergen induced airway remodeling
also demonstrated inhibition of airway remodeling but
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no effect on AHR measurements [15], consistent with
our observations in this study using Siglec-F deficient
mice.
In addition to investigating the effect of Siglec-F on
airway remodeling we examined whether the presence
versus absence of Siglec-F receptors influenced levels of
Siglec-F ligands being expressed. We have previously
demonstrated that levels of Siglec-F are upregulated on
blood eosinophils following OVA challenge [5]. In this
study we examined whether removal of the Siglec-F
receptor in Siglec-F deficient mice influenced levels of
Siglec-F ligand expression. Our study demonstrates that
the number of Siglec-F ligand+ peribronchial cells was
significantly increased in OVA challenged Siglec-F defi-
cient compared to OVA challenged WT mice. This
increase in level of peribronchial Siglec-F ligands in
Siglec-F deficient mice is most likely accounted for by
the increased numbers of inflammatory cells expressing
Siglec-F ligands (i.e. eosinophils, macrophages) recruited
to the airway following OVA challenge, though we can-
not rule out a contribution from upregulation of Siglec-
F ligand expression by inflammatory cells recruited to
the lung. In contrast, constitutive and OVA induced
levels of expression of the Siglec-F ligand in airway
epithelium are similar in Siglec-F deficient and WT
mice.
Conclusions
Overall, this study demonstrates an important role for
Siglec-F in modulating levels of chronic eosinophilic air-
way inflammation, peribronchial fibrosis, thickness of
the smooth muscle layer, fibronectin deposition, mucus
expression, and levels of peribronchial Siglec-F ligands
suggesting that Siglec-F may normally function to limit
levels of chronic eosinophilic inflammation, mucus, and
remodeling. As Siglec-F is not expressed on structural
cells in the lung such as fibroblasts, epithelial cells, or
smooth muscle cells, the enhanced remodeling is likely
due to enhanced airway inflammation in Siglec-F defi-
cient mice. Siglec-F deficient mice express significantly
increased numbers of peribronchial TGF-b1+ cell (but
not increased amounts of LTC4) suggesting that TGF-
b1 may be one possible mechanism of enhanced airway
remodeling in these mutant mice. In WT and Siglec-F
deficient mice airway epithelial Siglec-F ligand expres-
sion can be up-regulated by Th2 cytokines such as IL-4
or IL-13, but not by TNF-a, suggesting a potential
mechanism for airway epithelium to down regulate eosi-
nophilic inflammation. Insights from these studies of
Siglec-F deficient mice may have application to under-
standing the role of the human paralog of Siglec-F (i.e.
Siglec-8) [42] in humans with asthma and airway
remodeling.
List of abbreviations
ECP: Eosinophil Cationic Protein; LTC4: Leukotriene
C4: MBP: Major basic protein; OVA: Ovalbumin; PAS:
Periodic acid Schiff; Siglec-F: Sialic acid-binding Ig-
superfamily lectin-F; TGF-b1: Transforming growth fac-
tor beta 1.
Acknowledgements
This study was supported by NIH grants AI 38425 (DB), AI 70535(DB), AI
72115 (DHB, AV), and PO1-HL057345 (AV)
Dr Dae Jin Song’s current affiliation is: Department of Pediatrics, College of
Medicine, Korea University, Seoul, Korea.
Authors’ contributions
JYC, DJS, AP, PS, TD, and MM made significant contributions to design,
acquisition of data, as well as analysis and interpretation of data. SD made
significant contribution to acquisition of data. AV and DHB made significant
contributions to conception, design, analysis and interpretation of data, and
drafting of manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 November 2009 Accepted: 1 November 2010
Published: 1 November 2010
References
1. Crocker PR, Paulson JC, Varki A: Siglecs and their roles in the immune
system. Nat Rev Immunol 2007, 7:255-266.
2. Aizawa H, Zimmermann N, Carrigan PE, Lee JJ, Rothenberg ME, Bochner BS:
Molecular analysis of human Siglec-8 orthologs relevant to mouse
eosinophils: identification of mouse orthologs of Siglec-5 (mSiglec-F)
and Siglec-10 (mSiglec-G). Genomics 2003, 82:521-530.
3. Angata T, Hingorani R, Varki NM, Varki A: Cloning and characterization of a
novel mouse Siglec, mSiglec-F: differential evolution of the mouse and
human (CD33) Siglec-3-related gene clusters. J Biol Chem 2001,
276:45128-45136.
4. Tateno H, Crocker PR, Paulson JC: Mouse Siglec-F and human Siglec-8 are
functionally convergent paralogs that are selectively expressed on
eosinophils and recognize 6’-sulfo-sialyl Lewis × as a preferred glycan
ligand. Glycobiology 2005, 15:1125-1135.
5. Zhang M, Angata T, Cho JY, Miller M, Broide DH, Varki A: Defining the in
vivo function of Siglec-F, a CD33-related Siglec expressed on mouse
eosinophils. Blood 2007, 109:4280-4287.
6. Bochner BS, Alvarez RA, Mehta P, Bovin NV, Blixt O, White JR, Schnaar RL:
Glycan array screening reveals a candidate ligand for Siglec-8. J Biol
Chem 2005, 280:4307-4312.
7. Cho JY, Miller M, Baek KJ, Han JW, Nayar J, Lee SY, McElwain K, McElwain S,
Friedman S, Broide DH: Inhibition of airway remodeling in IL-5-deficient
mice. J Clin Invest 2004, 113:551-560.
8. Floyd H, Ni J, Cornish AL, Zeng Z, Liu D, Carter KC, Steel J, Crocker PR:
Siglec-8. A novel eosinophil-specific member of the immunoglobulin
superfamily. J Biol Chem 2000, 275:861-866.
9. Avril T, Floyd H, Lopez F, Vivier E, Crocker PR: The membrane-proximal
immunoreceptor tyrosine-based inhibitory motif is critical for the
inhibitory signaling mediated by Siglecs-7 and -9, CD33-related siglecs
expressed on human monocytes and NK cells. J Immunol 2004,
173:6841-6849.
10. Ravetch JV, Lanier LL: Immune inhibitory receptors. Science 2000,
290:84-89.
11. Nutku E, Aizawa H, Hudson SA, Bochner BS: Ligation of Siglec-8: a
selective mechanism for induction of human eosinophil apoptosis. Blood
2003, 101:5014-5020.
12. Vitale C, Romagnani C, Falco M, Ponte M, Vitale M, Moretta A, Bacigalupo A,
Moretta L, Mingari MC: Engagement of p75/AIRM1 or CD33 inhibits the
proliferation of normal or leukemic myeloid cells. Proc Natl Acad Sci USA
1999, 96:15091-15096.
Cho et al. Respiratory Research 2010, 11:154
http://respiratory-research.com/content/11/1/154
Page 13 of 14
13. von Gunten S, Yousefi S, Seitz M, Jakob SM, Schaffner T, Seger R, Takala J,
Villiger PM, Simon HU: Siglec-9 transduces apoptotic and nonapoptotic
death signals into neutrophils depending on the proinflammatory
cytokine environment. Blood 2005, 106:1423-1431.
14. Song DJ, Cho JY, Miller M, Strangman W, Zhang M, Varki A, Broide DH:
Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal
eosinophilic inflammation in a mouse model. Clin Immunol 2009,
131:157-169.
15. Song DJ, Cho JY, Lee SY, Miller M, Rosenthal P, Soroosh P, Croft M,
Zhang M, Varki A, Broide DH: Anti-Siglec-F antibody reduces allergen
induced eosinophilic inflammation and airway remodeling. J Immunol
2009, 183:5333-5341.
16. Zimmerman N, McBride ML, Yamada Y, Hudson SA, Jones C, Cromie KD,
Crocker PR, Rothenberg ME, Bochner BS: Siglec-F antibody administration
to mice selectively reduces blood and tissue eosinophils. Allergy 2008,
63:1156-1163.
17. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS,
Barnes N, Robinson D, Kay AB: Anti-IL-5 treatment reduces deposition of
ECM proteins in the bronchial subepithelial basement membrane of
mild atopic asthmatics. J Clin Invest 2003, 112:1029-1036.
18. Lim DH, Cho JY, Song DJ, Lee SY, Miller M, Broide DH: PI3K gamma-
deficient mice have reduced levels of allergen-induced eosinophilic
inflammation and airway remodeling. Am J Physiol Lung Cell Mol Physiol
2009, 296:L210-219, 22.
19. Christie PE, Henderson WR Jr: Lipid inflammatory mediators: leukotrienes,
prostaglandins, platelet-activating factor. Clin Allergy Immunol 2002,
16:233-254.
20. Henderson WR Jr, Tang LO, Chu SJ, Tsao SM, Chiang GK, Jones F, Jonas M,
Pae C, Wang H, Chi EY: A role for cysteinyl leukotrienes in airway
remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002,
165:108-116.
21. Thomas MJ, Smith A, Head DH, Milne L, Nicholls A, Pearce W,
Vanhaesebroeck B, Wymann MP, Hirsch E, Trifilieff A, Walker C, Finan P,
Westwick J: Airway inflammation: chemokine-induced neutrophilia and
the class I phosphoinositide 3-kinases. Eur J Immunol 2005, 35:1283-1291.
22. Le AV, Cho JY, Miller M, McElwain S, Golgotiu K, Broide DH: Inhibition of
allergen-induced airway remodeling in Smad 3-deficient mice. J Immunol
2007, 178:7310-7316.
23. Lim DH, Cho JY, Miller M, McElwain K, McElwain S, Broide DH: Reduced
peribronchial fibrosis in allergen-challenged MMP-9-deficient mice. Am J
Physiol Lung Cell Mol Physiol 2006, 291:L265-271.
24. Hudson SA, Bovin NV, Schnaar RL, Crocker PR, Bochner BS: Eosinophil-
selective binding and proapoptotic effect in vitro of a synthetic siglec-8
ligand, polymeric 6’-sulfated sialyl lewis X. J Pharmacol Exp Ther 2009,
330:608-612.
25. McMillan SJ, Xanthou G, Lloyd CM: Manipulation of allergen-induced
airway remodeling by treatment with anti-TGF-beta antibody: effect on
the Smad signaling pathway. J Immunol 2005, 174:5774-5780.
26. Fattouh R, Midence G, Arias K, Johnson J, Walker T, Goncharova S, Souza K,
Gregory R, Lonning S, Gauldie J, Jordana M: Transforming growth factor-β
regulates house dust mite-induced allergic airway inflammation but not
airway remodeling. Am J Repir Crit Care Med 2008, 177:593-603.
27. Alcorn J, Rinaldi L, Jaffe E, van Loon M, Bates J, Janssen-Heininger Y, Irvin C:
Transforming growth factor-β1 suppresses airway hyperresponsiveness
in allergic airway disease. Am J Respir Crit Care Med 2007, 176:974-982.
28. Deng H, Dokshin GA, Jing L, Goldsmith AM, Bitar KN, Fingar DC,
Hershenson MB, Bentley JK: Inhibition of glycogen synthase kinase-3β is
sufficient for airway smooth muscle hypertrophy. J Biol Chem 2008,
283:10198-10207.
29. Lundgren LD, Davey RT Jr, Lundgren B, Mullol J, Marom Z, Logun C,
Baraniuk J, Kaliner MA, Shelhamer JH: Eosinophil cationic protein
stimulates and major basic protein inhibits airway mucus secretion. J
Allergy Clin Immunol 1991, 87:689-698.
30. Ponikau JU, Sherris DA, Kephart GM, Kern EB, Congdon DJ, Adolphson CR,
Springett MJ, Gleich GJ, Kita H: Striking deposition of toxic eosinophil
major basic protein in mucus: Implications for chronic rhinosinusitis. J
Allergy Clin Immunol 2005, 116:362-369.
31. Lai HY, Rogers DF: Mucus hypersecretion in asthma: intracellular
signaling pathways as targets for pharmacotherapy. Curr Opin Allergy Clin
Immunol 2010, 10:67-76.
32. White ES, Baralle FE, Muro AF: New insights into form and function of
fibronectin splice variants. J Pathol 2008, 216:1-14.
33. Burgess JK: The role of the extracellular matrix and specific growth
factors in the regulation of inflammation and remodelling in asthma.
Pharmacol Ther 2009, 122:19-29.
34. Dolhnikoff M, da Silva LF, de Araujo BB, Gomes HA, Fernezlian S, Mulder A,
Lindeman JH, Mauad T: The outer wall of small airways is a major site of
remodeling in fatal asthma. J Allergy Clin Immunol 2009, 123:1090-1097.
35. McDonald JA, Kelley DG, Broekelmann T: Role of fibronectin in collagen
deposition: Fab’ to the gelatin-binding domain of fibronectin inhibits
both fibronectin and collagen organization in fibroblast extracellular
matrix. J Cell Biol 1982, 92:485-492.
36. Kato J, Kohyama T, Okazaki H, Desaki M, Nagase T, Rennard SI, Takizawa H:
Leukotriene D4 potentiates fibronectin-induced migration of human
lung fibroblasts. Clin Immunol 2005, 117:177-181.
37. Hirst SJ, Twort CH, Lee TH: Differential effects of extracellular matrix
proteins on human airway smooth muscle cell proliferation and
phenotype. Am J Respir Cell Mol Biol 2000, 23:335-344.
38. Chan V, Burgess JK, Ratoff JC, O’Connor BJ, Greenough A, Lee TH, Hirst SJ:
Extracellular matrix regulates enhanced eotaxin expression in asthmatic
airway smooth muscle cells. Am J Respir Crit Care Med 2006, 174:379-385.
39. James AL, Pare PD, Hogg JC: The mechanics in airway narrowing in
asthma. Am Rev Respir Dis 1989, 139:242-246.
40. Niimi A, Matsumoto H, Takemura M, Ueda T, Chin K, Mishima M:
Relationship of airway wall thickness to airway sensitivity and airway
reactivity in asthma. Am J Respir Crit Care Med 2003, 168:983-988.
41. Pare PD: Airway hyperresponsiveness in asthma geometry is not
everything! Am J Respir Crit Care Med 2003, 168:913-914.
42. Kikly KK, Bochner BS, Freeman S, Tan KB, Gallagher KT, D’Alessio K,
Holmes SD, Abrahamson J, Hopson CB, Fischer EI, Erickson-Miller CL,
Tachimoto H, Schleimer RP, White JR: Identification of SAF-2, a novel
siglec expressed on eosinophils, mast cells, and basophils. J Allergy Clin
Immunol 2000, 105:1093-1100.
doi:10.1186/1465-9921-11-154
Cite this article as: Cho et al.: Chronic OVA allergen challenged Siglec-F
deficient mice have increased mucus, remodeling, and epithelial Siglec-
F ligands which are up-regulated by IL-4 and IL-13. Respiratory Research
2010 11:154.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cho et al. Respiratory Research 2010, 11:154
http://respiratory-research.com/content/11/1/154
Page 14 of 14
